Activation of Sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6072-6079

  Teraishi, Fuminori ^a   Guo, Wei ^a   Zhang, Lidong ^a   Dong, Fengqing ^a   Davis, John J ^a   Sasazuki, Takehiko ^b   Shirasawa, Senji ^b   Liu, Jinsong ^a   Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HISTONE H2B; K RAS PROTEIN; LEPTOMYCIN B; PHOSPHOTRANSFERASE; PROTEIN MST 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL NUCLEUS; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASES; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; GENES, RAS; HCT116 CELLS; HISTONES; HUMANS; MUTATION; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 33745700212     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0125     Document Type: Article

References (45)

1. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994;78:773-85.
2. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
3. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
4. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
5. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-9.
6. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002;14:628-34.
7. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003;29:41-8.
8. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
9. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
10. Ayllon V, Rebollo A. Ras-induced cellular events [review]. Mol Membr Biol 2000;17:65-73.
11. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000;57:1613-36.
12. Brooks DG, James RM, Patek CE, Williamson J, Arends MJ. Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF). Oncogene 2001;20:2144-52.
13. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
14. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAP and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
15. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
16. Choi JA, Park MT, Kang CM, et al. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Oncogene 2004;23:9-20.
17. Klampfer L, Swaby LA, Huang J, et al. Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene 2005;24:3932-41.
18. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-ot-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004;64:3922-7.
19. Ninomiya Y, Kato K, Takahashi A, et al. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 2004;64:2759-65.
20. Khokhlatchev A, Rabizadeh S, Xavier R, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002;12:253-65.
21. Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA. Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J Biol Chem 2001;276:14909-15.
22. Kakeya H, Onose R, Osada H. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis. Cancer Res 1998;58:4888-94.
23. Lu ML, Sato M, Cao B, Richie JP. UV irradiation-induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells. Proc Natl Acad Sci U S A 1996;93:8977-82.
24. Graves JD, Gotoh Y, Draves KE, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 1998;17:2224-34.
25. Lee KK, Murakawa M, Nishida E, et al. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene 1998;16:3029-37.
26. Watabe M, Kakeya H, Onose R, Osada H. Activation of MST/Krs and c-Jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis. J Biol Chem 2000;275:8766-71.
27. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967-73.
28. Liu J, Yang G, Thompson-Lanza JA, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
29. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8.
30. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr., Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279:4339-45.
31. Teraishi F, Wu S, Sasaki J, et al. P-Glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2- (phenylamino)-4(5H)-thiazolone]. J Pharmacol Exp Ther 2005;314:355-62.
32. Teraishi F, Wu S, Zhang L, et al. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res 2005;65:6380-7.
33. Niv H, Gutman O, Henis YI, Kloog Y. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. J Biol Chem 1999;274:1606-13.
34. Zhu H, Zhang L, Dong F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005;24:4993-9.
35. de Souza PM, Lindsay MA, Mammalian Sterile20-like kinase 1 and the regulation of apoptosis. Biochem Soc Trans 2004;32:485-8.
36. Feig LA, Buchsbaum RJ. Cell signaling: life or death decisions of ras proteins. Curr Biol 2002;12:R259-61.
37. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem 2001;276:19276-85.
38. Ura S, Masuyama N, Graves JD, Gotoh Y. Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation. Proc Natl Acad Sci USA 2001;98:10148-53.
39. Ajiro K. Histone H2B phosphorylation in mammalian apoptotic cells. An association with DNA fragmentation. J Biol Chem 2000;275:439-43.
40. Kudo N, Matsumori N, Taoka H, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999;96:9112-7.
41. Hoa M, Davis SL, Ames SJ, Spanjaard BA Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002;62:7154-6.
42. Algarra I, Perez M, Serrano MJ, Garrido F, Gaforio JJ. c-K-ras overexpression is characteristic for metastases derived from a methylcholanthrene-induced fibrosarcoma. Invasion Metastasis 1998;18:261-70.
43. Patton SE, Martin ML, Nelsen LL, et al. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998;58:2253-9.
44. Ehrhardt A, David MD, Ehrhardt GR, Schrader JW. Distinct mechanisms determine the patterns of differential activation of N-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol Cell Biol 2004;24:6311-23.
45. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.